---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016253"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2022-08-10T23:59:59+00:00"
generated_at: "2026-06-24T01:30:49.323357+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TScan Q2 net loss $15.1M; cash $125.6M funds into 2024; TSC-101 IND cleared

## Summary
- Net loss $15.1M vs $10.7M in prior-year quarter; revenue $4.1M (up from $2.8M) on Novartis collaboration.
- Cash and equivalents $125.6M (plus $5M restricted); runway into 2024.
- FDA cleared IND for TSC-101 (HA-2) for HCT relapse prevention; Phase 1 umbrella trial now enrolling.
- Debora Barton, M.D., appointed Chief Medical Officer; brings cell therapy and oncology R&D experience.
- Plans to file INDs for solid-tumor candidates TSC-200-A2 (HPV) and TSC-204-C7 (MAGE-A1) by year-end 2022.

## SEC filing metadata
- accession: 0000950170-22-016253
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2022-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000095017022016253/0000950170-22-016253-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000095017022016253/tcrx-20220810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016253
- JSON: https://secwatch.observer/filing/0000950170-22-016253.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016253.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.